Abstract: The present disclosure relates to a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2), an active metabolite of the ADC, a method of producing the ADC, use of the ADC for the treatment and/or prevention of diseases, and use of the ADC for producing a drug for the treatment and/or prevention of diseases, more specifically hyperproliferative and/or angiogenic diseases, for example, cancer, and more particularly, to an antibody-drug conjugate including a novel antibody or antigen-binding fragment thereof that binds to CLDN18.2, and a pharmaceutical composition including the same.

Abstract: A manufacturing method of a cathode active material for lithium secondary battery, including: preparing a first solution by mixing a metal oxide and a solvent; preparing a metal-mixed solution by adding an acidic solution to the first solution and then applying ultrasonic waves to the mixture; centrifuging the metal-mixed solution; preparing a second solution by mixing a supernatant of the centrifuged metal-mixed solution, a reductant, and a solvent and then applying ultrasonic waves to the mixture; obtaining powder by filtering and then drying the second solution; forming mesoporous spherical nanoparticles by mixing the powder, a metal, a lithium precursor, and a solvent, applying ultrasonic waves to the mixture and then drying the mixture; and performing a heat treatment to the spherical nanoparticles, and a cathode active material for a lithium secondary battery obtained by the manufacturing method. The cathode active material for lithium secondary battery is mesoporous spherical nanoparticles.